Medivir AB MVR-FF:Frankfurt Stock Exchange

RT Quote | Exchange | EUR
Last | 02/26/21 CET
0.836quote price arrow up+0.02 (+2.45%)
52 week range
0.65 - 1.57

...

Loading . . .

KEY STATS

  • Open0.811
  • Day High0.836
  • Day Low0.811
  • Prev Close0.816
  • 52 Week High1.57
  • 52 Week High Date02/27/20
  • 52 Week Low0.65
  • 52 Week Low Date01/08/21
  • Market Cap29.71M
  • Shares Out29.58M
  • 10 Day Average Volume616.67
  • Dividend-
  • Dividend Yield-
  • Beta
  • 1 Year % Change-37.46

RATIOS/PROFITABILITY

  • EPS (TTM)-0.20
  • P/E (TTM)-4.18
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Medivir AB News

There is no recent news for this security.

Latest MVR-FF News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Medivir AB is a Sweden-based pharmaceutical research and development company with focus on oncology. The Company specializes in protease inhibitor design and nucleoside and nucleotide science, applying it to development of therapies for cancers with unmet medical need. The Company's clinical pipeline consists of remetinostat, a topical histone deacetylase (HDAC) inhibitor in phase II of clinical studies for the treatment of cutaneous T-cell lymphoma (CTCL), birinapant in...
Helena Levander
Chairman
Uli Hacksell Ph.D.
President
Magnus Christensen
Chief Financial Officer
Christina Herder Ph.D.
Executive Vice President
Address
Lunastigen 7
Huddinge
141 44
Sweden